Veru to Advance VERU-111 in P-III Study for COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Shots:
- The US FDA agreed to advance VERU-111 into a P-III study which will evaluate VERU-111 vs PBO in ~400 hospitalized patients in a ratio (2:1) with COVID-19 and are at high risk for ARDS. The study is anticipated to begin in Apr’2021 with clinical results expected in Q4’21
- The P-II trial has demonstrated clinically meaningful reductions in relevant endpoints- including respiratory failure- patient mortality- days in the ICU and mechanical ventilation and was well tolerated with a good safety profile
- The company will seek funding from BARDA to fund the estimated amount of commercial drug to supply the needs of the US population
Ref: GlobeNewswire | Image: Annual Reports
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com